BMEA NASDAQ
Biomea Fusion, Inc.
1W: -22.8%
1M: -40.5%
3M: -4.7%
YTD: -9.0%
1Y: -19.7%
3Y: -96.4%
5Y: -92.3%
$1.22
-0.03 (-2.40%)
Pre-Market: $1.26 (+0.04, +3.28%)
Weekly Expected Move ±11.5%
$1
$1
$1
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.1M
Congress—
ETF Holdings—
Key Statistics
Market Cap$72.6M
52W Range0.872-3.08
Volume1,093,789
Avg Volume1,512,616
Beta-0.34
Dividend—
Analyst Ratings
Company Info
CEOMichael J. Hitchcock
Employees79
SectorHealthcare
IndustryBiotechnology
IPO Date2021-04-16
Websitebiomeafusion.com
900 Middlefield Road
Redwood City, CA 94063
US
Redwood City, CA 94063
US
650 980 9099
About Biomea Fusion, Inc.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Latest News
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Erdtmann Rainer M | A-Award | 452,512 | $1.49 | 2026-04-01 |
| Hitchcock Michael J. | A-Award | 667,477 | $1.49 | 2026-04-01 |
| Erdtmann Rainer M | 0 | — | 2025-12-31 | |
| Erdtmann Rainer M | 0 | — | 2025-12-31 | |
| Erdtmann Rainer M | P-Purchase | 30,000 | $1.43 | 2025-12-11 |